Nkr-2
AML
Celyad Oncology SAPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
685 Active assets in the AML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Nkr-2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →